Romosozumab did not improve outcomes in patients with hip fractures
In patients with hip fractures, use of romosozumab did not improve clinical or radiographic outcomes, according to study results.
In a trial of 332 patients who underwent open reduction and internal fixation of intertrochanteric or femoral neck hip fractures, 243 patients were assigned to receive romosozumab (70 mg, n = 60; 140 mg, n = 93; and 210 mg, n = 90) and 89 patients were assigned to placebo on postoperative day 1 and at 2, 6 and 12 weeks. Difference in the mean timed up-and-go (TUG) score at 6 to 20 weeks postoperatively for romosozumab compared with placebo was the primary end point. Other end points included time to radiographic evidence of healing and the radiographic union scale for hip (RUSH) score.
Investigators found that although TUG scores improved, there was no statistically significant difference between the romosozumab and placebo groups from 6 to 20 weeks. Across the treatment groups, median time to radiographic evidence of healing was between 16.4 weeks and 16.9 weeks. The RUSH scores also improved in patients who received romosozumab and those who received placebo; however, the scores were not significantly different. Romosozumab was similar to placebo with regard to its overall safety and tolerability, according to researchers. – by Monica Jaramillo
Disclosure: The study was funded by Amgen Inc. and UCB Pharma.